Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2013; 19(32): 5334-5339
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5334
Table 4 Sex distribution of prevalence of dysmetabolic diseases and biochemical abnormalities in the 430 subjects with fatty liver n (%)
All patientsMale patientsFemale patientsχ2P value
Increased ALT and/or AST levels129 (30.0)113 (32.6)16 (19.3)5.630.018
Hypertriglyceridemia135 (31.4)125 (36.0)10 (12.0)17.87< 0.001
Mixed type hyperlipidemia90 (20.9)65 (18.7)25 (30.1)5.250.022
Hypercholesterolemia53 (12.3)33 (9.5)20 (24.1)13.19< 0.001
Hyperglycemia76 (17.6)59 (17.0)17 (20.5)0.560.455
Hypertension69 (16.0)53 (15.3)16 (19.3)0.800.372
Hyperuricemia66 (15.3)60 (17.3)6 (7.2)5.220.022
Gallstone62 (14.4)50 (14.4)12 (14.4)0.000.991
HBsAg34 (7.9)27 (7.9)7 (7.9)0.040.843
Increased Scr levels3 (0.7)3 (0.9)0 (0.0)--